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Neuroimaging continues to be an exciting and rapidly evolving research field producing findings to 
inform clinical medical practice. Neuroimaging research has enabled a better understanding of in vivo 
structural, functional and molecular neuropathology. Moreover, it has the potential to improve clinical 
care, where clinical assessment alone is sometimes insufficient to provide accurate diagnosis and 
prognosis. The future direction of neuroimaging is likely to focus on identifying imaging biomarkers 
suggestive of underlying preclinical disease, understanding the temporal progression from preclinical 
disease to overt clinical manifestation, and monitoring the therapeutic efficacy of potential disease-
modifying agents. 
 
A wide variety of brain imaging modalities have been utilised to investigate the most common mental 
disorders in the elderly, namely depression and dementia.  Indeed, advanced brain imaging has been 
instrumental in elucidating similar patterns of structural and functional brain abnormalities between 
the two conditions [1]. A key requirement for future research is to translate promising progress in 
these brain imaging studies into clinical practice, although, integration of neuroimaging into clinical 
practice may be impeded by economic considerations and patient acceptability. Economic barriers to 
integration include the potential cost to healthcare systems of modern imaging modalities. Therefore, 
studies focused on determining the minimal number of imaging modalities to provide clinically 
meaningful information and the added valve of each brain scan, are needed to address this question. 
Moreover, the increasing sensitivity of imaging to detect abnormal findings with uncertain significance 
may be psychologically distressing to patients and reduce their willingness to undergo such 
investigation. 
 
In this edition in their paper entitled “The psychological impact of disclosing amyloid status to 
Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline”, 
Wake T et al. explore the short-term psychological impact of disclosing Amyloid-β (Aβ) positron 
emission tomography (PET) results in  42 asymptomatic Japanese adults with subjective cognitive 
decline [2]. Importantly, all subjects underwent pre-imaging counselling/education detailing the role 
of Aβ in the evolution of cognitive decline and the interpretation of PET results. Of the 42 participants, 
10 had an Aβ positive result and 32 had an Aβ negative result, no between group differences were 
noted in measures of anxiety and depression at pre- and post-disclosure of amyloid neuroimaging 
status. Moreover, mean state anxiety and depression scores were below the normal limits in the pre- 
and post-disclosure in Aβ positive and negative groups.  Full disclosure of Aβ positive status did not 
cause a greater change in anxiety and depression measures than negative results after a six-week 
period. This study attempts to address the psychological safety of full disclosure of positive 
neuroimaging results detected by advanced neuroimaging techniques, a concern that has become a 
major ethical issue due to the increasing application of amyloid imaging in disease-modifying clinical 
trials in Alzheimer’s disease (AD). These reassuring findings replicate earlier studies addressing this 
important question in cognitively normal older adults in the USA but do so in a cohort of subjects from 
a different ethnic and cultural background to previous studies [3]. Furthermore, this is a first study to 
investigate this question among individuals with subjective cognitive decline, who may be potentially 
more anxious about their self-perceived risk of cognitive decline. This study suggests clinicians may 
fully disclose positive amyloid scan results without inducing any negative psychological sequelae, 
providing the necessary groundwork of pre-scan explanation has been completed. 
 
In an investigation addressing the important health economics question about the best use of limited 
healthcare resources and the value of additional neuroimaging to provide clinically meaning 
information, Guinane et al recruited a convenience sample from their memory clinic [4]. Specifically 
they explored the beneficial role of additional MRI and/or SPECT brain imaging to routine diagnostic 
workup to improve diagnostic accuracy in a memory assessment encompassing a non-contrast CT 
brain. Over a 12 month period, 66 out of 253 patients were referred for additional imaging with 
subjects undergoing MRI only (n=15), SPECT (n=6), and MRI & SPECT (n=29) and 16 being excluded. 
The overall referral rate for additional MRI and/or SPECT in this study was modest at 26%, likely 
because subjects had all had structural CT.  Diagnostic amendments occurred in 11/44 (25%) of 
subjects with MRI scan and 9/35 (26%) where SPECT was used.  Those who were referred for additional 
imaging were significantly younger, more educated and more likely to have a head injury. Previous 
studies have reported a higher referral rate for, and a positive outcome rate using MRI and SPECT 
imaging in a clinical setting [5].  This study suggests that in selected cases there can be added value to 
such additional imaging but the scope to which this study is applicable to a clinical setting remains 
limited. However, it does highlight the need for further research in this area to inform future clinical 
guidelines for diagnostic imaging in the memory clinic. 
 
Tau imaging is an exciting research area and in addition to enlightening the early stages and progress 
of the tauopathy of Alzheimer’s disease this imaging modality will inform us about other forms of 
tauopathy. In their paper Takaya et al examined two patients with frontotemporal lobe degeneration 
associated with different types of aphasia [6]. They used 18F-THK-5351 positron emission tomography 
to identify tau deposits in two subjects with variants of primary progressive aphasia (PPA) who had 
also had negative amyloid imaging assessed using Pittsburgh compound B (PiB). Both subjects also 
underwent MRI imaging and FDG-PET imaging, demonstrating fronto-temporal atrophy and 
concomitant cortical hypometabolism consistent with fronto-temporal dementia–related PPA. Based 
on current diagnostic criteria, one patient was diagnosed as semantic variant of PPA, a subtype of 
frontotemporal lobe degeneration (FTLD) and the other as logopenic PPA.  
 
Previous studies,  in late-life depression have identified widespread functional connectivity alterations 
[7] and in this edition of International Psychogeriatics, Zhu et al advance our understanding by 
applying a graph theoretical approach to assess the role of the default mode network (DMN) [8]. 
Specifically they examined whether resting-state fMRI could detect alternations in functional 
connectivity and topological organisation of the default-mode network (DMN) in patients with 
remitted geriatric depression (RGD) compared with healthy controls. In comparison to the 31 healthy 
controls, the 33 RGD showed reduced functional connectivity in the posterior regions of the DMN and 
abnormal global topology of the DMN. Neuropsychological measures of processing speed and 
executive function correlated with network abnormalities noted on fMRI. Longitudinal studies have 
previously shown the patients with RGD have an increased risked risk of cognitive decline [1].  Given 
the correlation between neuropsychological measures and resting-state fMRI measures of the DMN, 
these network measures could be used as a potential biomarker of cognitive impairment in RGD. 
 
Vasudev A. et al. assessed the role of ventromedial prefrontal cortex (vMPFC) in regulating emotional 
control in late-life depression as assessed using emotional valence to blood oxygenation level-
dependent (BOLD) functional magnetic resonance imaging (fMRI) and the burden of total brain white 
matter hyperintensities (WMH) [9]. This study differed from prior studies in this field by examining the 
role of the vMPFC in both genders and by using a combination of structural and functional brain 
imaging. In this small cross-sectional study, 16 subjects with mild to moderate late-life depression 
were compared to 14 aged matched healthy controls. As expected WMH volume was greater in the 
late-life depression group than in the health controls. There was no difference in BOLD activation 
between groups in terms of emotional valence contrast but interestingly, a gender difference was 
noted with female subjects with late-life depression having both more WMH volume and reduced 
BOLD activation in the vMPFC than controls. The results of this study concords with prior work with 
female LLD patients showing reduced activation of the vMPFC to negatively valenced word in a fMRI 
task [10]. The finding in this study are intriguing and require confirmation in a larger study. 
 
In conclusion, the five articles outlined above, illustrate the increasing capabilities of sophisticated 
brain imaging techniques and reassure that disclosure of imaging findings after appropriate patient 
education is not detrimental to the psychological wellbeing of patients. Advanced imaging techniques 
are capable of uncovering the relationships between cognitive impairment, depression, gender and 
brain network alterations.  Brain network alterations in the DMN has the potential to be a biomarker 
of cognitive dysfunction among RGD patients. Reduced activation of the vMPFC among female 
patients with LLD is an interesting finding which needs to be explored in larger sample size. In the 
clinical setting, there may be added value of MRI and/or SPECT to current diagnostic work-up in a 
memory clinic but further studies in field would are required. and the application of tau imaging 
among the rarer clinical phenotypes of dementia has much potential.  Whilst these studies show some 
of the opportunities, the translation of research findings into routine clinical care will be a painstaking 
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